Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProMIS NeurosciencesPMN -2.19%35 3-1 Month Momentum % is 35.84% as of Aug. 12, 2026. GuruFocus rates PMN with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, ProMIS Neurosciences ranks better than 91.49% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-12), ProMIS Neurosciences's 3-1 Month Momentum % is 35.84%.
The industry rank for ProMIS Neurosciences's 3-1 Month Momentum % or its related term are showing as below:
PMN's 3-1 Month Momentum % is ranked better than 91.49% of 1386
companies
in the Biotechnology industry
Industry Median: -7.05
vs PMN: 35.84
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ProMIS Neurosciences 3-1 Month Momentum % Related Terms
PMN vs FBIO, VANI, SEER: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, ProMIS Neurosciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProMIS Neurosciences (PMN) has a 3-1 Month Momentum % of 35.84% as of Aug. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ProMIS Neurosciences and its competitors. According to the industry distribution chart, ProMIS Neurosciences ranks #118 out of 1386 companies in the Biotechnology industry, placing it in the top 8.5%.
Is ProMIS Neurosciences' 3-1 Month Momentum % too high?
ProMIS Neurosciences' current 3-1 Month Momentum % is 35.84%. Based on the distribution chart, ProMIS Neurosciences ranks #118 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' 3-1 Month Momentum % compare to FBIO and VANI?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #118 out of 1386 companies for 3-1 Month Momentum %. This places ProMIS Neurosciences in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current 3-1 Month Momentum % is 35.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current 3-1 Month Momentum % of 35.84%. The current 3-1 Month Momentum % is 35.84%. ProMIS Neurosciences' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current 3-1 Month Momentum % is 35.84% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
35GF Score
Get the complete analysis for PMN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
